跳至主要内容
临床试验/NCT02219698
NCT02219698已完成不适用

Symptomatic Treatment of Acute Uncomplicated Diverticulitis

Helsinki University Central Hospital1 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
158
试验地点
1
主要终点
Complications of diverticulitis

研究概览

简要总结

The purpose of this study is to determine the safety and efficacy of symptomatic treatment (i.e. without antimicrobial drugs) of acute uncomplicated diverticulitis.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Computed tomography-diagnosed acute uncomplicated* diverticulitis
  • No abscess, fistula, obstruction and distant intra- or retroperitoneal air. Pericolic air allowed.

排除标准

  • Already commenced antimicrobial medication
  • Immunosuppression (e.g. diabetes, corticosteroid medication, immunosuppressive medication, chemotherapy, chronic liver disease)
  • Suspicion of generalized peritonitis
  • Organ dysfunction
  • Another infection requiring antimicrobial medication
  • Pregnancy
  • Age < 18 years or > 90 years
  • Missing written consent

研究组 & 干预措施

Symptomatic treatment

Experimental

干预措施: Ibuprofen (Drug)

Symptomatic treatment

Experimental

干预措施: Paracetamol (Drug)

结局指标

主要结局

Complications of diverticulitis

时间窗: 30 days from allocation

Incidence of complications of diverticulitis (abscess, free perforation, need for surgery)

次要结局

  • Need for emergency surgery for diverticulitis on another admission(10 years)
  • Commencement of antimicrobial drug(For the duration of hospital stay, an expected average of 2 days)
  • Late complication of diverticulitis(10 years)
  • Stoma rate(10 years)
  • Length of hospital stay (days)(At the end of the hospital stay, an expected average of 2 days)
  • Rate of re-admissions(30 days from discharge)
  • Recurrence of diverticulitis(10 years)
  • Mortality(30 days from allocation)
  • Need for elective sigmoid resection(10 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ville Sallinen

M.D., Ph.D.

Helsinki University Central Hospital

研究点 (1)

Loading locations...

相似试验